Molecular Heterogeneity of the Brain Endothelium

The blood–brain barrier (BBB) is part of a neurovascular structure located in the brain’s micro vessels, that is essential to maintain brain homeostasis, but prevents the brain uptake of most drugs. Because of its importance in neuro-pharmacotherapy, the BBB has been the subject of extensive research since its discovery over 100 years ago. Major advances in understanding the structure and function of the barrier have been made. Drugs are re-designed to cross the BBB. However, despite these efforts, overcoming the BBB efficiently to treat brain diseases safely remains challenging. The majority of BBB research studies focus on the BBB as a homogenous structure throughout the different brain regions. However, this simplification may lead to an inadequate understanding of the BBB function with significant therapeutic consequences. From this perspective, we analyzed the gene and protein expression profiles of the BBB in the micro vessels from the brains of mice that were isolated from two different brain regions, namely the cortex and the hippocampus. The expression profile of the inter-endothelial junctional protein (claudin-5), three ABC transporters (P-glycoprotein, Bcrp and Mrp-1), and three BBB receptors (lrp-1, TRF and GLUT-1) were analyzed. Our gene and protein analysis showed that the brain endothelium in the hippocampus exhibits different expression profiles compared to the brain cortex. Specifically, brain endothelial cells (BECs) of the hippocampus express higher gene levels of abcb1, abcg2, lrp1, and slc2a1 compared to the BECs of the cortex regions with a trend of increase for claudin-5, while BECs of the cortex express higher gene levels of abcc1 and trf compared to the hippocampus. At the protein levels, the P-gp expression was found to be significantly higher in the hippocampus compared to the cortex, while TRF was found to be up-regulated in the cortex. These data suggest that the structure and function of the BBB are not homogeneous, and imply that drugs are not delivered similarly among the different brain regions. Appreciation of the BBB heterogeneity by future research programs is thus critical for efficient drug delivery and the treatment of brain diseases.

[1]  R. Hamoudi,et al.  miR-623 Targets Metalloproteinase-1 and Attenuates Extravasation of Brain Metastatic Triple-Negative Breast Cancer Cells , 2022, Breast cancer.

[2]  Ryota L. Matsuoka,et al.  Historical and current perspectives on blood endothelial cell heterogeneity in the brain , 2022, Cellular and Molecular Life Sciences.

[3]  P. Carmeliet,et al.  Deciphering endothelial heterogeneity in health and disease at single-cell resolution: progress and perspectives , 2022, Cardiovascular research.

[4]  M. Lawton,et al.  A single-cell atlas of the normal and malformed human brain vasculature , 2022, Science.

[5]  R. Hamoudi,et al.  miR-27a-3p regulates expression of intercellular junctions at the brain endothelium and controls the endothelial barrier permeability , 2022, PloS one.

[6]  R. Hamoudi,et al.  Regulation of P-glycoprotein by miR-27a-3p at the brain endothelial barrier. , 2021, Journal of pharmaceutical sciences.

[7]  M. Trepel,et al.  Vascular Endothelial Cells: Heterogeneity and Targeting Approaches , 2021, Cells.

[8]  P. Reddy,et al.  The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease , 2021, Cells.

[9]  Liqun He,et al.  Key molecular alterations in endothelial cells in human glioblastoma uncovered through single-cell RNA sequencing , 2021, JCI insight.

[10]  R. Hamoudi,et al.  Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells , 2021, Breast Cancer Research and Treatment.

[11]  S. Liebner,et al.  Developmental regulation of barrier‐ and non‐barrier blood vessels in the CNS , 2021, Journal of internal medicine.

[12]  Ryota L. Matsuoka,et al.  Endothelial cell-type-specific molecular requirements for angiogenesis drive fenestrated vessel development in the brain , 2021, eLife.

[13]  T. Nowakowski,et al.  The Expanding Cell Diversity of the Brain Vasculature , 2020, Frontiers in Physiology.

[14]  A. Tlili,et al.  Silencing miR-202-3p increases MMP-1 and promotes a brain invasive phenotype in metastatic breast cancer cells , 2020, PloS one.

[15]  David T. Paik,et al.  Single-Cell RNA-seq Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells. , 2020, Circulation.

[16]  R. Hamoudi,et al.  Loss of miR-101-3p Promotes Transmigration of Metastatic Breast Cancer Cells through the Brain Endothelium by Inducing COX-2/MMP1 Signaling , 2020, Pharmaceuticals.

[17]  Divya Sharma,et al.  GLUT-1 an effective target to deliver BDNF gene across blood brain barrier. , 2020, ACS chemical neuroscience.

[18]  F. Remião,et al.  Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. , 2020, Pharmacology & therapeutics.

[19]  Ziying Liu,et al.  Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human , 2020, Fluids and Barriers of the CNS.

[20]  L. Bolund,et al.  Single-Cell Transcriptome Atlas of Murine Endothelial Cells , 2020, Cell.

[21]  A. Malik,et al.  Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation , 2020, eLife.

[22]  Donald W. Miller,et al.  Modulation of Wnt/β-catenin signaling promotes blood-brain barrier phenotype in cultured brain endothelial cells , 2019, Scientific Reports.

[23]  C. Erice,et al.  The Evolving Concept of the Blood Brain Barrier (BBB): From a Single Static Barrier to a Heterogeneous and Dynamic Relay Center , 2019, Front. Cell. Neurosci..

[24]  C. Greene,et al.  Claudin-5: gatekeeper of neurological function , 2019, Fluids and Barriers of the CNS.

[25]  F. Calon,et al.  Transferrin Receptor-Mediated Uptake at the Blood-Brain Barrier Is Not Impaired by Alzheimer's Disease Neuropathology. , 2019, Molecular pharmaceutics.

[26]  James T. Webber,et al.  Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris , 2018, Nature.

[27]  S. Weggen,et al.  The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM , 2018, Brain, Behavior, and Immunity.

[28]  Evan Z. Macosko,et al.  Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain , 2018, Cell.

[29]  M. Stins,et al.  Brain vascular heterogeneity: implications for disease pathogenesis and design of in vitro blood–brain barrier models , 2018, Fluids and Barriers of the CNS.

[30]  Koji Ando,et al.  A molecular atlas of cell types and zonation in the brain vasculature , 2018, Nature.

[31]  K. Plate,et al.  Functional morphology of the blood-brain barrier in health and disease , 2018, Acta Neuropathologica.

[32]  W. Pardridge.  Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology , 2017, BioDrugs.

[33]  M. Gessler,et al.  Gene expression profiles of brain endothelial cells during embryonic development at bulk and single-cell levels , 2017, Science Signaling.

[34]  G. Bu,et al.  Role of LRP1 in the pathogenesis of Alzheimer’s disease: evidence from clinical and preclinical studies , 2017, Journal of Lipid Research.

[35]  L. Collin,et al.  Region-specific permeability of the blood–brain barrier upon pericyte loss , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  M. Suciu,et al.  Differences in the molecular structure of the blood-brain barrier in the cerebral cortex and white matter: an in silico, in vitro, and ex vivo study. , 2016, American journal of physiology. Heart and circulatory physiology.

[37]  S. Barger,et al.  A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid β -Peptide from the Brain. , 2016, Current Alzheimer research.

[38]  H. Galla,et al.  Blood-brain barrier properties in vitro depend on composition and assembly of endogenous extracellular matrices , 2016, Cell and Tissue Research.

[39]  G. Fricker,et al.  ABC transporters at the blood–brain barrier , 2016, Expert opinion on drug metabolism & toxicology.

[40]  A. Kim,et al.  Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier , 2016, Current pharmaceutical design.

[41]  C. Greene,et al.  Tight junction modulation of the blood brain barrier: CNS delivery of small molecules , 2016, Tissue barriers.

[42]  M. Suciu,et al.  Heterogeneity of the blood-brain barrier , 2016, Tissue barriers.

[43]  T. Bayer,et al.  Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier. , 2015, The Journal of clinical investigation.

[44]  S. Miyata.  New aspects in fenestrated capillary and tissue dynamics in the sensory circumventricular organs of adult brains , 2015, Front. Neurosci..

[45]  J. Geurts,et al.  Pathological differences between white and grey matter multiple sclerosis lesions , 2015, Annals of the New York Academy of Sciences.

[46]  D. Walsh,et al.  Autoregulated paracellular clearance of amyloid-β across the blood-brain barrier , 2015, Science Advances.

[47]  F. Carvalho,et al.  Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. , 2015, Pharmacology & therapeutics.

[48]  J. Ghersi-Egea,et al.  Efflux transporters in blood-brain interfaces of the developing brain , 2015, Front. Neurosci..

[49]  C. Beyer,et al.  Absence of CCL2 and CCL3 Ameliorates Central Nervous System Grey Matter But Not White Matter Demyelination in the Presence of an Intact Blood–Brain Barrier , 2015, Molecular Neurobiology.

[50]  R. Daneman,et al.  The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.

[51]  B. Gidal.  P-glycoprotein Expression and Pharmacoresistant Epilepsy: Cause or Consequence? , 2014, Epilepsy currents.

[52]  A. Mabondzo,et al.  P-glycoprotein, breast cancer resistance protein, Organic Anion Transporter 3, and Transporting Peptide 1a4 during blood-brain barrier maturation: involvement of Wnt/β-catenin and endothelin-1 signaling. , 2013, Molecular pharmaceutics.

[53]  W. Banks,et al.  Susceptibility of juvenile and adult blood–brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity , 2012, Journal of Neuroinflammation.

[54]  H. D. de Vries,et al.  The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids , 2012, Front. Pharmacol..

[55]  C. Beyer,et al.  Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination , 2012, Journal of Molecular Neuroscience.

[56]  Christoph W. Blau,et al.  Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury , 2012, Nature Communications.

[57]  W. Aird,et al.  Endothelial cell heterogeneity. , 2012, Cold Spring Harbor perspectives in medicine.

[58]  K. M. Baeten,et al.  Extracellular matrix and matrix receptors in blood–brain barrier formation and stroke , 2011, Developmental neurobiology.

[59]  Sagar Agarwal,et al.  Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. , 2011, Current pharmaceutical design.

[60]  A. Hartz,et al.  ABC transporters in the CNS - an inventory. , 2011, Current pharmaceutical biotechnology.

[61]  Bengt R. Johansson,et al.  Pericytes regulate the blood–brain barrier , 2010, Nature.

[62]  B. Barres,et al.  Pericytes are required for blood–brain barrier integrity during embryogenesis , 2010, Nature.

[63]  Berislav V. Zlokovic,et al.  Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging , 2010, Neuron.

[64]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[65]  P. Humphries,et al.  An experimental platform for systemic drug delivery to the retina , 2009, Proceedings of the National Academy of Sciences.

[66]  Martin Stangel,et al.  Regional differences between grey and white matter in cuprizone induced demyelination , 2009, Brain Research.

[67]  Á. Kittel,et al.  A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes , 2009, Neurochemistry International.

[68]  K. Leenders,et al.  Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA , 2008, Journal of Neural Transmission.

[69]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[70]  K. Hayashi,et al.  Pericytes from Brain Microvessels Strengthen the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells , 2007, Cellular and Molecular Neurobiology.

[71]  H. D. de Vries,et al.  The Blood-Brain Barrier in Cortical Multiple Sclerosis Lesions , 2007, Journal of neuropathology and experimental neurology.

[72]  W. Aird.  Phenotypic Heterogeneity of the Endothelium: II. Representative Vascular Beds , 2007, Circulation research.

[73]  L. Homolya,et al.  Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1) , 2007, Pflügers Archiv - European Journal of Physiology.

[74]  M. Nedergaard,et al.  Astrocyte End-Feet in Germinal Matrix, Cerebral Cortex, and White Matter in Developing Infants , 2006, Pediatric Research.

[75]  E. Masliah,et al.  Altered P‐Glycoprotein Expression in AIDS Patients with HIV Encephalitis , 2004, Journal of neuropathology and experimental neurology.

[76]  B. Sarkadi,et al.  ABCG2 – a transporter for all seasons , 2004, FEBS letters.

[77]  D. Begley,et al.  ABC transporters and the blood-brain barrier. , 2004, Current pharmaceutical design.

[78]  K. Kim,et al.  Induction of Intercellular Adhesion Molecule-1 on Human Brain Endothelial Cells by HIV-1 gp120: Role of CD4 and Chemokine Coreceptors , 2003, Laboratory Investigation.

[79]  M. Bendayan.  Morphological and cytochemical aspects of capillary permeability , 2002, Microscopy research and technique.

[80]  M Thom,et al.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. , 2002, Brain : a journal of neurology.

[81]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[82]  Jullie W Pan,et al.  Differentiation of Glucose Transport in Human Brain Gray and White Matter , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[83]  C. Achim,et al.  Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. , 1999, The American journal of pathology.

[84]  M. Weinand,et al.  Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. , 1999, The American journal of pathology.

[85]  S. Tsukita,et al.  Endothelial Claudin , 1999, The Journal of cell biology.

[86]  R. Dempsey,et al.  The biphasic opening of the blood–brain barrier in the cortex and hippocampus after traumatic brain injury in rats , 1997, Neuroscience Letters.

[87]  L. Rubin,et al.  A cell culture model of the blood-brain barrier , 1991, The Journal of cell biology.

[88]  G. Goldstein,et al.  Endothelial Cell‐Astrocyte Interactions , 1988, Annals of the New York Academy of Sciences.

[89]  Z. Nagy,et al.  Tight junctions of brain endothelium in vitro are enhanced by astroglia , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[90]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .